Lv3
332 积分 2025-01-02 加入
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges
12小时前
待确认
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
7天前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
7天前
已完结
Trends in the drug target landscape for autoimmune diseases
9天前
已完结
In vivo manufacture and manipulation of CAR-T cells for better druggability
16天前
已完结
In vivo CAR T cells move into clinical trials
16天前
已完结
Defining immune reset: achieving sustained remission in autoimmune diseases
1个月前
已完结
Inherited human IRAK-4 deficiency: an update
1个月前
已完结
Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B
2个月前
已完结
OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
2个月前
已完结
皖公网安备34019202002308
